Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 179

1.

NADPH oxidase 1 mediates α-synucleinopathy in Parkinson's disease.

Cristóvão AC, Guhathakurta S, Bok E, Je G, Yoo SD, Choi DH, Kim YS.

J Neurosci. 2012 Oct 17;32(42):14465-77. doi: 10.1523/JNEUROSCI.2246-12.2012.

2.

NADPH oxidase 1-mediated oxidative stress leads to dopamine neuron death in Parkinson's disease.

Choi DH, Cristóvão AC, Guhathakurta S, Lee J, Joh TH, Beal MF, Kim YS.

Antioxid Redox Signal. 2012 May 15;16(10):1033-45. doi: 10.1089/ars.2011.3960. Epub 2012 Jan 25.

3.

shRNA targeting α-synuclein prevents neurodegeneration in a Parkinson's disease model.

Zharikov AD, Cannon JR, Tapias V, Bai Q, Horowitz MP, Shah V, El Ayadi A, Hastings TG, Greenamyre JT, Burton EA.

J Clin Invest. 2015 Jul 1;125(7):2721-35. doi: 10.1172/JCI64502. Epub 2015 Jun 15.

4.

Reprint of: revisiting oxidative stress and mitochondrial dysfunction in the pathogenesis of Parkinson disease-resemblance to the effect of amphetamine drugs of abuse.

Perfeito R, Cunha-Oliveira T, Rego AC.

Free Radic Biol Med. 2013 Sep;62:186-201. doi: 10.1016/j.freeradbiomed.2013.05.042. Epub 2013 Jun 3. Review.

PMID:
23743292
5.

A progressive dopaminergic phenotype associated with neurotoxic conversion of α-synuclein in BAC-transgenic rats.

Nuber S, Harmuth F, Kohl Z, Adame A, Trejo M, Schönig K, Zimmermann F, Bauer C, Casadei N, Giel C, Calaminus C, Pichler BJ, Jensen PH, Müller CP, Amato D, Kornhuber J, Teismann P, Yamakado H, Takahashi R, Winkler J, Masliah E, Riess O.

Brain. 2013 Feb;136(Pt 2):412-32. doi: 10.1093/brain/aws358.

6.

Rab1A over-expression prevents Golgi apparatus fragmentation and partially corrects motor deficits in an alpha-synuclein based rat model of Parkinson's disease.

Coune PG, Bensadoun JC, Aebischer P, Schneider BL.

J Parkinsons Dis. 2011;1(4):373-87. doi: 10.3233/JPD-2011-11058.

PMID:
23939344
7.

α-Synuclein and mitochondrial bioenergetics regulate tetrahydrobiopterin levels in a human dopaminergic model of Parkinson disease.

Ryan BJ, Lourenço-Venda LL, Crabtree MJ, Hale AB, Channon KM, Wade-Martins R.

Free Radic Biol Med. 2014 Feb;67:58-68. doi: 10.1016/j.freeradbiomed.2013.10.008. Epub 2013 Oct 19.

8.

Aldehyde dehydrogenase 1 defines and protects a nigrostriatal dopaminergic neuron subpopulation.

Liu G, Yu J, Ding J, Xie C, Sun L, Rudenko I, Zheng W, Sastry N, Luo J, Rudow G, Troncoso JC, Cai H.

J Clin Invest. 2014 Jul;124(7):3032-46. doi: 10.1172/JCI72176. Epub 2014 May 27.

10.

Oxidative stress-induced posttranslational modifications of alpha-synuclein: specific modification of alpha-synuclein by 4-hydroxy-2-nonenal increases dopaminergic toxicity.

Xiang W, Schlachetzki JC, Helling S, Bussmann JC, Berlinghof M, Schäffer TE, Marcus K, Winkler J, Klucken J, Becker CM.

Mol Cell Neurosci. 2013 May;54:71-83. doi: 10.1016/j.mcn.2013.01.004. Epub 2013 Jan 28.

PMID:
23369945
11.

Treatment with Trehalose Prevents Behavioral and Neurochemical Deficits Produced in an AAV α-Synuclein Rat Model of Parkinson's Disease.

He Q, Koprich JB, Wang Y, Yu WB, Xiao BG, Brotchie JM, Wang J.

Mol Neurobiol. 2016 May;53(4):2258-68. doi: 10.1007/s12035-015-9173-7. Epub 2015 May 14.

PMID:
25972237
12.

Lewy body extracts from Parkinson disease brains trigger α-synuclein pathology and neurodegeneration in mice and monkeys.

Recasens A, Dehay B, Bové J, Carballo-Carbajal I, Dovero S, Pérez-Villalba A, Fernagut PO, Blesa J, Parent A, Perier C, Fariñas I, Obeso JA, Bezard E, Vila M.

Ann Neurol. 2014 Mar;75(3):351-62. doi: 10.1002/ana.24066. Epub 2014 Feb 18.

PMID:
24243558
13.

PKCδ mediates paraquat-induced Nox1 expression in dopaminergic neurons.

Cristóvão AC, Barata J, Je G, Kim YS.

Biochem Biophys Res Commun. 2013 Aug 2;437(3):380-5. doi: 10.1016/j.bbrc.2013.06.085. Epub 2013 Jul 2.

14.

FOXO3 determines the accumulation of α-synuclein and controls the fate of dopaminergic neurons in the substantia nigra.

Pino E, Amamoto R, Zheng L, Cacquevel M, Sarria JC, Knott GW, Schneider BL.

Hum Mol Genet. 2014 Mar 15;23(6):1435-52. doi: 10.1093/hmg/ddt530. Epub 2013 Oct 24.

PMID:
24158851
15.

Zonisamide attenuates α-synuclein neurotoxicity by an aggregation-independent mechanism in a rat model of familial Parkinson's disease.

Arawaka S, Fukushima S, Sato H, Sasaki A, Koga K, Koyama S, Kato T.

PLoS One. 2014 Feb 20;9(2):e89076. doi: 10.1371/journal.pone.0089076. eCollection 2014.

16.

Chronic intranasal deferoxamine ameliorates motor defects and pathology in the α-synuclein rAAV Parkinson's model.

Febbraro F, Andersen KJ, Sanchez-Guajardo V, Tentillier N, Romero-Ramos M.

Exp Neurol. 2013 Sep;247:45-58. doi: 10.1016/j.expneurol.2013.03.017. Epub 2013 Mar 24.

PMID:
23531432
17.
18.

Aggregated alpha-synuclein activates microglia: a process leading to disease progression in Parkinson's disease.

Zhang W, Wang T, Pei Z, Miller DS, Wu X, Block ML, Wilson B, Zhang W, Zhou Y, Hong JS, Zhang J.

FASEB J. 2005 Apr;19(6):533-42.

PMID:
15791003
19.

Heat shock protein 70 reduces α-synuclein-induced predegenerative neuronal dystrophy in the α-synuclein viral gene transfer rat model of Parkinson's disease.

Moloney TC, Hyland R, O'Toole D, Paucard A, Kirik D, O'Doherty A, Gorman AM, Dowd E.

CNS Neurosci Ther. 2014 Jan;20(1):50-8. doi: 10.1111/cns.12200. Epub 2013 Nov 27.

PMID:
24279716
20.

Trib3 Is Elevated in Parkinson's Disease and Mediates Death in Parkinson's Disease Models.

Aimé P, Sun X, Zareen N, Rao A, Berman Z, Volpicelli-Daley L, Bernd P, Crary JF, Levy OA, Greene LA.

J Neurosci. 2015 Jul 29;35(30):10731-49. doi: 10.1523/JNEUROSCI.0614-15.2015.

Supplemental Content

Support Center